Healthcare
Live Price
Offline$122.18
+2.37% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Boston Scientific Corporation (BSX-PA) is a Healthcare stock with a market cap of $175.45B. The stock last traded around $122.18. Baseline metrics include revenue growth of +19.9%, EPS growth of +55.6%, a dividend yield of 0.0%. What stands out right now is revenue +19.9%, EPS +55.6%, free cash flow +38.3% with operating margin 20.1% and ROIC 9.9%. Valuation sits in the middle of the pack at P/E 23.4 and price/sales 4.0. Stock Foundry combines BSX-PA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BSX-PA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BSX-PA Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BSX-PA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$11.9B
-6.3% YoY
FY Net Income
$1.0B
+49.0% YoY
Free Cash Flow
$1.3B
+44.0% YoY
Revenue Growth
+19.9%
EPS Growth
+55.6%
Gross Margin
70.4%
Net Margin
17.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 20.1B | 16.7B | 14.2B | 12.7B | 11.9B |
| Gross Profit | 13.9B | 10.3B | 8.8B | 7.7B | 7.5B |
| Operating Income | 4.0B | 2.6B | 2.2B | 1.8B | 1.9B |
| EBITDA | 3.7B | 3.9B | 3.5B | 2.7B | 2.5B |
| Net Income | 2.9B | 1.9B | 1.6B | 698M | 1.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.0B | 414M | 865M | 928M | 1.9B |
| Total Assets | 43.7B | 39.4B | 35.1B | 32.5B | 32.2B |
| Total Liabilities | 19.2B | 17.4B | 15.6B | 14.9B | 15.6B |
| Shareholder Equity | 24.2B | 21.8B | 19.3B | 17.6B | 16.6B |
| Total Debt | 12.4B | 11.1B | 9.5B | 9.3B | 9.5B |
| Net Debt | 10.4B | 10.7B | 8.6B | 8.4B | 7.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.9B
+22.5% YoY
Capital Expenditures
554M
+9.5% YoY
Free Cash Flow
1.3B
+44.0% YoY
Key ratios
Gross Margin
70.4%
Operating Margin
20.1%
Net Margin
17.2%
ROE
14.8%
Debt / Equity
0.43x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.